TAKEDA PHARMACEUTICAL CO LTD ADR

NYSE: TAK (Takeda Pharmaceutical Company L)

Last update: 3 days ago, 12:53PM

14.96

0.04 (0.23%)

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - Specialty & Generic (US) Mixed Mixed
Drug Manufacturers - Specialty & Generic (Global) Mixed Mixed
Stock Takeda Pharmaceutical Company L Mixed Mixed

Stockmoo Score

-0.3

Similar Stocks

Stock Market Cap DY P/E P/B
TAK 48 B 1,260.05% 46.73 0.860
ZTS 84 B 0.91% 36.24 16.78
HLN 39 B 1.76% 28.80 2.21
RDY 13 B 0.58% 19.95 3.88
TEVA 21 B - - 3.22
CTLT 11 B - - 3.02

Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Investment Style Large Core

Ownership

Name Date Shares Held
Managed Asset Portfolios, Llc 30 Jun 2024 1,613,472

No data within this time range.

No data within this time range.

  • 3M
Date Type Details
07 Aug 2024 Announcement Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
31 Jul 2024 Announcement Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline
26 Jun 2024 Announcement Takeda Announces New Assignments of Directors
24 Jun 2024 Announcement Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
22 Jun 2024 Announcement Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
21 Jun 2024 Announcement Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
18 Jun 2024 Announcement Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
17 Jun 2024 Announcement Takeda Announces Phase 3 Topline Results for Soticlestat (TAK-935) in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome
14 Jun 2024 Announcement Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)
11 Jun 2024 Announcement Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts
TTM Dividend Yield 1,260.05%
5Y Average Dividend Yield 4.23%
Ex Date Announcement Date Payment Date Details
30 Mar 2023 15 Mar 2023 10 Jul 2023 0.30996 Cash
29 Sep 2022 13 Sep 2022 12 Dec 2022 0.329553 Cash
30 Mar 2022 04 Mar 2022 11 Jul 2022 0.330062 Cash
29 Sep 2021 - 13 Dec 2021 0.396898 Cash
30 Mar 2021 15 Mar 2021 12 Jul 2021 0.406627 Cash
29 Sep 2020 - 11 Dec 2020 0.430533 Cash
30 Mar 2020 - 06 Jul 2020 0.419053 Cash
27 Sep 2019 09 Sep 2019 12 Dec 2019 0.411118 Cash
28 Mar 2019 16 Mar 2019 10 Jul 2019 0.417168 Cash
26 Sep 2018 - 13 Dec 2018 0.395501 Cash
27 Mar 2018 - 09 Jul 2018 0.40643 Cash
27 Sep 2017 - 11 Dec 2017 0.39946 Cash
29 Mar 2017 - 10 Jul 2017 0.39892 Cash
28 Sep 2016 - 12 Dec 2016 0.392415 Cash
29 Mar 2016 - 11 Jul 2016 0.43705 Cash
28 Sep 2015 - 11 Dec 2015 0.365323 Cash
27 Mar 2015 - 09 Jul 2015 0.365289 Cash
25 Sep 2014 - 11 Dec 2014 0.378342 Cash
26 Mar 2014 - 10 Jul 2014 0.443655 Cash
25 Sep 2013 - 12 Dec 2013 0.436978 Cash
26 Mar 2013 - 08 Jul 2013 0.457131 Cash
25 Sep 2012 - 13 Dec 2012 0.545983 Cash
27 Mar 2012 - 09 Jul 2012 0.563768 Cash
27 Sep 2011 - 12 Dec 2011 0.578629 Cash
28 Mar 2011 - 07 Jul 2011 0.555761 Cash
27 Sep 2010 - 13 Dec 2010 0.533229 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2023 0.310 1 2.17
2022 0.660 2 4.23
2021 0.804 2 5.90
2020 0.850 2 4.67
2019 0.828 2 4.20
2018 0.802 2 4.77
2017 0.798 2 2.81
2016 0.829 2 3.99
2015 0.731 2 2.92
2014 0.822 2 3.96
2013 0.894 2 3.88
2012 1.11 2 5.00
2011 1.13 2 5.15
2010 0.533 1 2.19
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria